DIA
17.10.2018 08:02:04 CEST | Business Wire | Press release
DIA , founded as the Drug Information Association, announced three keynote speakers for the upcoming DIA Europe 2019 annual meeting: Dave deBronkart, ‘e-Patient Dave’; Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics; and Kristel Van der Elst, CEO, The Global Foresight Group. The diversity of experience brought by these three leaders is reflective of the meeting mission to ensure industry, payers, patients, and regulators all have an equal voice in the debates advancing regulatory science and access to healthcare.
These keynote speakers will join 300 speakers in more than 80 sessions, across seven thought leadership streams to drive collaborative answers in medicines development and access to healthcare. Highlights from sessions include Guido Rasi, Executive Director, EMA, will present first look strategies for 2021-2025 during the European Regulatory Town Hall and Niklas Hedberg, Chair EUnetHTA Executive Board, will feature case studies of Real World Evidence in Market Access . All sessions and speaker details can be viewed in the recently launched and continuously updated Searchable Programme . The Programme Highlights provides an overview of the key successes from DIA Europe 2018 and the direction conversations will take in 2019. Cross-functional dialogues will address cutting-edge topics such as the Evolution of Science and Policy , Modern Clinical Research , Access to Medicines , and Digital Disruptors .
The annual meeting theme of, “Join Us at the Crossroads of Healthcare”, continues to emphasize the multi-stakeholder, outcome-driven dialogue that occurs at the DIA Europe annual meeting. “Stakeholders come from across the world to hear about how Europe is approaching some of the most important issues of the day for regulatory science, for patients, and for how healthcare is going to develop not only here in Europe, but clearly what contributions we have to make to the broader global debates,” as Virginia Acha, Executive Director, Global Regulatory Policy, MSD and member of the DIA Europe Steering Committee, shared in a recent video interview .
Critically important for all development and access stakeholders is understanding current policies as well as future pathways for regulatory science. DIA Europe 2019 brings together representatives from over 35 regulatory, HTA, and patient advocacy agencies throughout the globe, including European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Federal Institute for Drugs and Medical Devices (BfArM), Pharmaceuticals and Medical Devices Agency (PMDA), and the Austrian Medicines and Medical Devices Agency (AGES).
“The DIA Europe 2018 annual meeting set a high bar both in terms of attendance and level of engagement. We look forward to building upon that momentum of confronting the tough challenges facing drug development professionals. While DIA’s history has its roots in bringing together regulatory professionals, we’ve evolved to address the interconnectedness of all functions and facilitate discussions across the entire drug development spectrum – from discovery to marketed use. 2019 will be no different,” details Thomas Bols, Senior Vice President and Managing Director for DIA Europe, Middle East, and Africa (EMEA).
To learn more and register for DIA Europe 2019 visit, DIAglobal.org/Europe2019 . For live updates, follow and join the conversation on Twitter, @DIA_Europe using the hashtag #DIAEurope2019.
About DIA
DIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from more than 80 countries have affected healthcare outcomes, by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities.
DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan).
For more information, visit DIAglobal.org or connect with DIA on Twitter , LinkedIn , Facebook , and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005167/en/
Contact:
DIA Jacqueline Zeller, Marketing Jacqueline.Zeller@DIAglobal.org
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide8.4.2026 18:00:00 CEST | Press release
Part of the Visa Intelligent Commerce portfolio, Intelligent Commerce Connect will enable more ways for agents to pay and merchants to accept agentic transactions in a single integrationCurrently in pilot with select partners including Aldar, AWS, Diddo, Highnote, Mesh, Payabli, Sumvin, and rolling out to more partners this year Visa Inc. (NYSE: V) today unveiled Intelligent Commerce Connect, a new solution that makes it easier for businesses to connect to and participate in AI-powered commerce. Intelligent Commerce Connect acts as a network, protocol, and token vault-agnostic ‘on ramp’ to agentic commerce for agent builders, merchants, and enablers. As consumers increasingly rely on AI agents to make purchases, businesses – whether they are building agents, selling to them, or processing transactions – need a simple way to get started. Intelligent Commerce Connect, part of the Visa Intelligent Commerce portfolio, meets that need. Through a single integration via the Visa Acceptance Pl
Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield Complete the Acquisition of Air Lease Corporation8.4.2026 15:13:00 CEST | Press release
Sumitomo Corporation, SMBC Aviation Capital, Apollo-managed funds (“Apollo”) and Brookfield today announced that they have completed the previously announced acquisition of Air Lease Corporation (“Air Lease”) and have renamed the business Sumisho Air Lease Corporation (“Sumisho Air Lease”). This transformational transaction improves the financial position of the business with long term support and aviation expertise from co-investors Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield. Sumisho Air Lease’s strong foundation as an established aircraft lessor, supported by SMBC Aviation Capital’s industry‑leading capabilities as servicer, creates a platform with the scale and financial strength needed to meet the fast‑changing and increasingly complex requirements of airline customers. Sumisho Air Lease will also benefit from the deep expertise and long-standing commitment that both Sumitomo Corporation and SMBC Aviation Capital bring to the global aviation leasing sector.
Sitetracker Launches Scout, an Agentic AI Platform Purpose-Built for Critical Infrastructure8.4.2026 15:00:00 CEST | Press release
Sitetracker, the leading Asset Lifecycle Management platform for critical infrastructure, today announced the launch of Scout, its new Agentic AI platform designed to help infrastructure owners, operators, and contractors gain deep insights and drive automation within their operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408923336/en/ Scout, ready for real work As your AI analyst and agent, Scout is ready to work on day 1. Scout provides clarity when decisions are forming and momentum when action is required. It surfaces risk, synthesizes information, and helps accelerate execution by connecting data and driving action. Scout creates operational intelligence and turns it into action all in a secure environment that protects data sovereignty. “Our customers are looking to create compounding competitive advantages,” said Giuseppe Incitti, Chief Executive Officer of Sitetracker. “Scout delivers by providing easy t
Westinghouse Hosts Annual VVER Fuel Forum with Customers8.4.2026 15:00:00 CEST | Press release
Westinghouse currently has fuel supply contracts with all the European VVER operators Westinghouse and MVM Paks Nuclear Power Plant (NPP) recently co-hosted the VVER Fuel Forum in Budapest to share insights and plans for the continued deployment of VVER-1000 and VVER-440 fuel in operating reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408646373/en/ Participants to the VVER Fuel Forum Péter János Horváth, CEO of MVM Paks, welcomed all the participants, highlighting that Hungary is ending two decades of single supplier fuel dependency thanks to the agreement recently signed with Westinghouse to supply the VVER-440 NOVA E-6 fuel design. Six customers presented the progress made and positive outcomes achieved in the past years with the introduction of Westinghouse fuel into mixed cores with resident fuel in their reactors: Energoatom has extensive experience with Westinghouse VVER-440 and VVER-1000 fuel, currently u
Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production Enhancers8.4.2026 15:00:00 CEST | Press release
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs.Virica and FUJIFILM Biosciences will co-develop an off-the-shelf enhancer–media solution to boost AAV yields and process robustness in FUJIFILM Biosciences BalanCD® HEK293 system. Virica Biotech (“Virica”), a cell enhancer company specializing in Viral Sensitizers (VSE™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), under the Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The collaboration will focus on optimizing a VSE™ formulation for FUJIFILM Biosciences BalanCD HEK293 media to support academic and commercial AAV producers globally. AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
